PhaseBio Pharmaceuticals, Inc. Announces Positive Clinical Results with its Once Weekly GLP-1 analogue, Glymera™ for the Treatment of Hyperglycemia in Patients with Type 2 Diabetes
11/15/2011 11:16:02 AM
MALVERN, Pa.--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc., announced today positive results from its Phase I/IIa single and multiple ascending dose clinical study with Glymera™, a recombinant glucagon-like peptide-1 (GLP-1) analogue for the treatment of hyperglycemia in patients with type 2 diabetes. In a dose dependent manner, Glymera™ demonstrated highly statistically significant reductions in fasting glucose glycemic load following meal tolerance testing, and average daily glucose measured through continuous glucose monitoring following 4 weeks of dosing.
comments powered by